Special Issue "Botulinum Toxin A on Lower Urinary Tract Dysfunction"
Deadline for manuscript submissions: closed (31 January 2016)
Botulinum toxin A is a potent protein that can selectively modulate neurotransmission from nerve endings, resulting in blocking of neurotransmitter release and causing muscular paralysis. Recent evidence also revealed that botulinum toxin A has mechanism acting on sensory receptors and an anti-inflammatory effect. Injection of onabotulinumtoxinA into the urethral sphincter results in a reduction of urethral resistance and improves voiding efficiency. Detrusor overactivity is also suppressed by intravesical onabotulinumtoxinA injections, which results in reduction in detrusor pressure and decreased urinary incontinence and daily frequency. In lower urinary tract dysfunction, onabotulinumtoxinA has recently received regulatory approval for the treatment of adult patients with neurogenic detrusor overactivity due to spinal cord lesions, multiple sclerosis, and idiopathic overactive bladder. Although unapproved, onabotulinumtoxinA has been widely used to treat patients with neurogenic or non-neurogenic voiding dysfunction, male lower urinary tract symptoms due to benign prostatic hyperplasia or bladder-neck dysfunction. Other indications to which urologists have applied onabotulinumtoxinA in recent decades include interstitial cystitis/bladder pain syndrome, bladder oversensitivity, and chronic pelvic pain syndrome. This review focuses on recent clinical trials and researches on the therapeutic effects of onabotulinumtoxinA on lower urinary tract dysfunction. The basic science which support the clinical application of onabotulinumtoxinA on lower urinary tract dysfunction will be covered in this Special Issue. The technical points, adverse events, and patients’ satisfaction and adherence to this novel treatment will also be discussed.
Prof. Hann-Chorng Kuo, M.D.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lower urinary tract dysfunction
- overactive bladder
- interstitial cystitis
- neurogenic bladder